Exhibit 99.1
 
VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
 
South San Francisco, Calif., October 29, 2018 – VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today reported financial results for its fiscal 2019 second quarter ended September 30, 2018.
 
“During the quarter, we continued to focus our resources on AV-101 development, especially advancement of ELEVATE, our Phase 2 adjunctive treatment study for major depressive disorder, and Phase 3-enabling nonclinical and regulatory activities. ELEVATE is well underway, and we remain confident in our target to deliver topline results in mid-2019,” said Shawn Singh, Chief Executive Officer of VistaGen.
 
“In addition to advancing our core AV-101 development programs, we also recently enhanced our pipeline with two complementary assets aimed at the treatment of CNS disorders with high unmet need. We signed exclusive license agreements to develop and commercialize these potential first-in-class, intranasally administered, new drug candidates, PH94B for social anxiety disorder and PH10 for major depressive disorder. We believe adding these two potential rapid-onset neuroactive steroid treatments, together with AV-101, which is focused on achieving rapid-onset antidepressant effects through NMDA and AMPA receptors, adds significant pipeline strength and gives us the potential to provide patients with a broad range of potential new generation solutions to treat depression and other CNS disorders with serious unmet need, with the goal of eliminating psychological side effects and safety concerns often associated with current therapies” concluded Mr. Singh.
 
Operational Highlights:
 
Continued Advancements in the Clinical Development of AV-101
 
In connection with our initial collaboration with the U.S. Department of Veteran’s Affairs (VA) and Baylor University (Baylor), Baylor commenced a randomized, double-blind, first-step, cross-over study in healthy volunteer U.S. Military Veterans to define a dose-response relationship between AV-101 and relevant biomarkers related to NMDA function believed to be associated with suicidal ideation. The results of this initial study could lead to a Phase 2 study involving AV-101 and U.S. Military Veterans who are battling suicidal thoughts or behaviors.
 
We received FDA Fast Track Designation (FTD) for development of AV-101 as a non-opioid treatment for neuropathic pain, without sedative or psychological side effects. Together with our FTD for development of AV-101 for major depressive disorder (MDD), this is the second FTD we have received from the FDA for AV-101 since December 2017, marking another milestone for our regulatory team.
 
License Agreements to Acquire Two First-in-Class CNS Drug Candidates
 
Acquired a license for exclusive worldwide rights to develop and commercialize PH94B, a pivotal Phase 3-ready drug candidate with potential to be the first FDA-approved acute on-demand medication for social anxiety disorder (SAD), a widespread social phobia which, according to the Anxiety and Depression Association of America, affects as many as 15 million American adults.
 
Acquired a license for exclusive worldwide rights to develop and commercialize PH10, a potential first-in-class, intranasally administered neuroactive steroid with rapid-onset antidepressant effects for MDD as demonstrated in a Phase 2a study. We believe PH10 is likely to have rapid-onset antidepressant effects within hours, not days or weeks, similar to ketamine-based drug candidates, but potentially without the psychological side effects, safety issues or required in-clinic administration.
 
 
 
 
 
Financial Results for the Fiscal Quarter Ended September 30, 2018:
 
Net loss attributable to common stockholders for the fiscal quarter ended September 30, 2018 was approximately $7.7 million, compared to $5.3 million for the fiscal quarter ended September 30, 2017, primarily attributable to increased research and development activities relating to the Company’s AV-101 programs and noncash expense of $2.25 million to acquire the exclusive license to PH94B and exclusive option to license PH10.
 
Research and development expense totaled approximately $5.3 million for the fiscal quarter ended September 30, 2018, compared with approximately $2.4 million for the fiscal quarter ended September 30, 2017. The increase is primarily attributable to expenses related to conducting ELEVATE and AV-101 Phase 3-enabling nonclinical and regulatory activities, including manufacturing process improvements and production of additional quantities of AV-101 drug substance, coupled with the acquisition of the exclusive license to PH94B and the exclusive option to licensePH10 through the issuance of our common stock, which acquisitions resulted in $2.25 million of noncash expense.
 
General and administrative expense was approximately $2.2 million in the fiscal quarter ended September 30, 2018, compared to approximately $2.6 million in the fiscal quarter ended September 30, 2017.
 
At September 30, 2018, the Company had cash and cash equivalents of approximately $7.8 million, compared to approximately $10.4 million at March 31, 2018. Since September 30, 2018, as a result of self-placed private placement transactions of unregistered securities to accredited investors and exercises of outstanding warrants, the Company has received aggregate cash proceeds of approximately $2.4 million.
 
About VistaGen
VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. For more information, please visit www.vistagen.com and connect with VistaGen on TwitterLinkedIn and Facebook.
 
Forward-Looking Statements
This release contains various statements concerning VistaGen's future expectations, plans and prospects, including without limitation, our expectations regarding development and commercialization of our drug candidates, including AV-101 for MDD, neuropathic pain and suicidal ideation, PH94B for SAD, and PH10 for MDD, as well as our intellectual property and commercial protection of our drug candidates, all of which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and may cause actual results to differ materially from those contemplated in these forward-looking statements. Among these risks is the possibility that (i) we may encounter unexpected adverse events in patients during our clinical development of any product candidate that cause us to discontinue further development, (ii) we may not be able to successfully demonstrate the safety and efficacy of our product candidates at each stage of clinical development, (iii) success in preclinical studies or in early-stage clinical trials may not be repeated or observed in ongoing or future studies, and ongoing or future preclinical and clinical results may not support further development of, or be sufficient to gain regulatory approval to market AV-101, PH94B, and/or PH10, (iv) decisions or actions of regulatory agencies may negatively affect the progress of, and our ability to proceed with, further clinical studies or to obtain marketing approval for our drug candidates, (v) we may not be able to obtain or maintain adequate intellectual property protection and other forms of marketing and data exclusivity for our product candidates, (vi) we may not have access to or be able to secure substantial additional capital to support our operations, including our ongoing clinical development activities; and (vii) we may encounter technical and other unexpected hurdles in the manufacturing and development of any of our product candidates. Certain other risks are more fully discussed in the section entitled "Risk Factors" in our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission (SEC). Our SEC filings are available on the SEC's website at www.sec.gov. In addition, any forward-looking statements represent our views only as of the issuance of this release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.
 
Company Contact
Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com
 
Investor Contact
Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com
 
Media Contact
Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com
 
 
 
 
 
 
VISTAGEN THERAPEUTICS
Consolidated Balance Sheets
(Amounts in dollars, except share amounts)
 
 
 
September 30,
 
 
March 31,
 
 
 
 2018
 
 
 2018
 
 
 
(Unaudited)
 
 
(Note 2)
 
 
 
 
 
 
 
 
ASSETS
Current assets:
 
 
 
 
 
 
 Cash and cash equivalents
 $7,831,600 
 $10,378,300 
 Prepaid expenses and other current assets
  648,000 
  644,800 
 Total current assets
  8,479,600 
  11,023,100 
Property and equipment, net
  361,800 
  207,400 
Security deposits and other assets
  47,800 
  47,800 
 Total assets
 $8,889,200 
 $11,278,300 
 
    
    
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
    
    
 Accounts payable
 $590,100 
 $1,195,700 
 Accrued expenses
  599,700 
  206,300 
 Current notes payable
  115,600 
  53,900 
 Capital lease obligations
  2,800 
  2,600 
 Total current liabilities
  1,308,200 
  1,458,500 
 
    
    
Non-current liabilities:
    
    
 Accrued dividends on Series B Preferred Stock
  3,165,400 
  2,608,300 
 Deferred rent liability
  418,500 
  285,600 
 Capital lease obligations
  7,900 
  9,300 
 Total non-current liabilities
  3,591,800 
  2,903,200 
 Total liabilities
  4,900,000 
  4,361,700 
 
    
    
Commitments and contingencies
    
    
 
    
    
Stockholders’ equity:
    
    
Preferred stock, $0.001 par value; 10,000,000 shares authorized at September 30, 2018 and March 31, 2018:
    
    
Series A Preferred, 500,000 shares authorized, issued and outstanding at September 30, 2018 and March 31, 2018
  500 
  500 
Series B Preferred; 4,000,000 shares authorized at September 30, 2018 and March 31, 2018; 1,160,240 shares issued and outstanding at September 30, 2018 and March 31, 2018
  1,200 
  1,200 
Series C Preferred; 3,000,000 shares authorized at September 30, 2018 and March 31, 2018; 2,318,012 shares issued and outstanding at September 30, 2018 and March 31, 2018
  2,300 
  2,300 
Common stock, $0.001 par value; 100,000,000 shares authorized at September 30, 2018 and March 31, 2018; 28,676,715 and 23,068,280 shares issued and outstanding at September 30, 2018 and March 31, 2018, respectively
  28,700 
  23,100 
Additional paid-in capital
  176,117,900 
  167,401,400 
Treasury stock, at cost, 135,665 shares of common stock held at September 30, 2018 and March 31, 2018
  (3,968,100)
  (3,968,100)
Accumulated deficit
  (168,193,300)
  (156,543,800)
Total stockholders’ equity
  3,989,200 
  6,916,600 
Total liabilities and stockholders’ equity
 $8,889,200 
 $11,278,300 
 
 
 
 
 
 
VISTAGEN THERAPEUTICS
CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
 
Amounts in Dollars, except share amounts
 
 
 
Quarters Ended
September 30,
 
 
 Six Months Ended
September 30,
 
 
 
2018
 
 
2017
 
 
2018
 
 
2017
 
Operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
 $5,261,100 
 $2,426,600 
 $8,004,800 
 $3,522,800 
General and administrative
  2,171,000 
  2,567,100 
  3,637,300 
  3,731,400 
Total operating expenses
  7,432,100 
  4,993,700 
  11,642,100 
  7,254,200 
Loss from operations
  (7,432,100)
  (4,993,700)
  (11,642,100)
  (7,254,200)
Other expenses, net:
    
    
    
    
Interest expense, net
  (2,900)
  (3,300)
  (5,000)
  (5,700)
 
    
    
    
    
Loss before income taxes
  (7,435,000)
  (4,997,000)
  (11,647,100)
  (7,259,900)
Income taxes
  - 
  - 
  (2,400)
  (2,400)
Net loss and comprehensive loss
  (7,435,000)
  (4,997,000)
  (11,649,500)
  (7,262,300)
 
    
    
    
    
Accrued dividend on Series B Preferred stock
  (283,600)
  (256,300)
  (557,100)
  (503,600)
 
    
    
    
    
Net loss attributable to common stockholders
 $(7,718,600)
 $(5,253,300)
 $(12,206,600)
 $(7,765,900)
 
    
    
    
    
Basic and diluted net loss attributable to common
    
    
    
    
stockholders per common share
 $(0.30)
 $(0.53)
 $(0.50)
 $(0.82)
 
    
    
    
    
Weighted average shares used in computing basic
    
    
    
    
and diluted net loss attributable to common
    
    
    
    
stockholders per common share
  25,815,245 
  9,892,016 
  24,267,816 
  9,465,459